SOVREMENNYE PREDSTAVLENIYa OB ANTIBAKTERIAL'NOY TERAPII INFEKTsII MOChEVOY SISTEMY U DETEY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The choice of tactics of treatment and prevention of exacerbations of urinary tract infections in children is one of the most difficult and controversial issues of pediatric nephrology. The article presents current data on drugs and treatment regimens for children with microbial-inflammatory diseases of the urinary tract. The potentials for application of various antibacterial agents in terms of their effectiveness and safety are considered. It is emphasized that unified solution of this problem from the perspective of evidence-based medicine has not yet been found, despite the number of studies evaluating the effectiveness, methods of administration and duration of courses of antibiotic therapy of urinary tract infections in children.

Full Text

Restricted Access

References

  1. Федеральная служба государственной статистики Росстат http://www.gks.ru
  2. Царегородцев А.Д., Игнатова М.С. Заболевания органов мочевой системы у детей // Российский вестник перинатологии и педиатрии 2001. Т. 46. № 4. С. 25-9.
  3. Соматичекие болезни у детей. Руководство для врачей / Под ред. М.С. Игнатовой. Москва-Оренбург, 2002. 669 с.
  4. Bhat R.G., Katy T.A., Place F.C. Pediatric urinary tract infections. Emerg Med Clin North Am 2011; 29(3): 637-53.
  5. Beetz R. Evaluation and management of urinary tract infections in the neonate. Curr Opin Pediatr 2012 Jan 5. Epub ahead of print.
  6. Lin D.S., Huang S.H., Lin C.C., et al. Urinary tract infection in febrile infants younger than eight weeks of age. Pediatrics 2000; 105(2): Е20.
  7. Remington J.S., Klein J. Infectious diseases of the fetus and newborn. 5th edition Philadelphia: W.B. Saunders, 2001.
  8. Farmaki E., Papachristou F., Winn R.M., et al. Transforming growth factor-beta1 in the urine of young children with urinary tract infection. Pediatr Nephrol 2005; 20(2): 180-83.
  9. Sevketoglu E., Yilmaz A., Gedikbasi A., et al. Urinary macrophage migration inhibitory factor in children with urinary tract infection. Pediatr Nephrol 2010; 25(2): 299-304.
  10. Stojiljkovic N. Glomerular basement membrane alterations induced by gentamicin administration in rats. Expel Toxicol Pathol 2008; 60(1): 69-75.
  11. Kaynar K., Gul S., Ersoz S., et al. Amikacin-induced nephropathy: is there any protective way? Ren Fail 2007; 29(1): 23-7.
  12. El Mouedden M., Guy Laurent G., Mingeot-Leclercq M.-P., et al. Apoptosis in renal proximal tubules of rats treated with low doses of aminoglycosides. Antimicrob Agents Chemother 2000; 44(3): 665-75.
  13. Bando M., Hasegawa M., Tsuboi Y., et al. The mycotoxin penicillin acid inhibits Fas Ligand-iduced apoptosis by blocking self-processing of caspase-8 in death-inducing signaling complex. J Biol Chem 2003; 278(8): 5786-93.
  14. Yoon J.E., Kim W.K., Lee J.S., Shin K.S., Ha T.S. Antibiotic susceptibility and imaging findings of the causative microorganisms responsible for acute urinary tract infection in children: a five-year single center study. Korean J Pediatr 2011; 54(2): 79-85.
  15. Copp H.L., Shapiro D.J., Hersh A.L. National ambulatory antibiotic prescribing patterns for pediatric urinary tract infection, 1998-2007. Pediatrics 2011; 127(6): 1027-33.
  16. Mohkam M., Karimi A., Gharib A., et al. Ceftriaxone associated nephrolithiasis: a prospective study in 284 children. Pediatr Nephrol 2007; 22(5): 690-94.
  17. Biner B., Oner N., Celtik C., et al. Ceftriaxone-associated biliary pseudolithiasis in children. J Clin Ultrasound 2006; 34(5): 217-22.
  18. Lorz C., Justo P., Subira D., et al. Paracetamol-induced renal tubular injury: a role for ER stress. J Am Soc Nephrol 2004; 15(2): 380-89.
  19. Hodson E.M., Willis N.S., Craig J.C. Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev. 2007; 4: CD003772.
  20. Shah G., Upadhyay J. Controversies in the diagnosis and management of urinary tract infections in children. Paediatr Drugs 2005; 7(6): 339-46.
  21. Bocquet N., Sergent Alaoui A., Jais J.P., et al. Randomized Trial of Oral Versus Sequential IV/Oral Antibiotic for Acute Pyelonephritis in Children. Pediatrics 2012; 129: e269-e275.
  22. Michael M., Hodson E.M., Craig J.C., et al. Short compared with standard duration of antibiotic treatment for urinary tract infection: a systematic review of randomised controlled trials. Arch Dis Child 2002; 87: 118-23.
  23. Mangiarotti P., Pizzini C., Fanos V. Antibiotic prophylaxis in children with relapsing urinary tract infections: review. J Chemother 2000; 12(2): 115-23.
  24. Georgaki-Angelaki H., Kostaridou S., Daikos G.L., et al. Long-term follow-up of children with vesicoureteral reflux with and without antibiotic prophylaxis. Scand J Infect Dis 2005; 37(11-12): 842-45.
  25. Pennesi M., Travan L., Peratoner L., et al. Is antibiotic profylaxis in children with VUR effective in preventing pyelonephritis and renal scars? A randomized controlled trial. Pediatrics 2008; 121(6): 1489-94.
  26. Verier-Jones K., et al. Effectiveness of antibiotic prophylaxis for children at risk of developing UTI and renal scarring: Results of systematic review carried out on behalf of the National Institute for Health and Clinical Excellence (NICE), UK. Pediatric Nephrol 2008; 23(9): 1595.
  27. Раменская Г.В. Изучение сравнительной фармакокинетики препаратов Фурамаг и Фурагин // Инфекции и антимикробная терапия 2004. Т. 6. № 1. С. 34-35 (http://www.consilium-medicum.com/infektion/04_01/34.shtm
  28. Перепанова Т.С. и др. Проблемы лечения рецидивирующей инфекции нижних мочевых путей. Урология. 2011. № 3. С. 1-5.
  29. Шатохина О.В. Сравнительная эффективность противорецидивной терапии фурагином и фурамагом при инфекции мочевой системы у детей // Вестник педиатрической фармакологии и нутрициологиию 2006. Т. 3. № 6. С. 1-4.
  30. Османов И.М., Ключников С.О., Гаджиалиева М.М. Фурамаг в терапии инфекции мочевой системы у детей // Рос. вестник перинатол. и педиатр. 2010. № 4. С. 110-112.
  31. Zafriri D., Ofek I., Adar R., et al. Inhibitory activity of cranberry juice on adherence of type 1 and type P fimbriated Escherichia coli to eucaryotic cells. Antimicrob Agents Chemother 1989; 33(1): 92-8.
  32. Liu Y., Black M.A., Caron L., Camesano T.A. Role of cranberry juice on molecular-scale surface characteristics and adhesion behavior of Escherichia coli. Biotechnol Bioeng 2006; 93(2): 297-305.
  33. Salo J., Uhari M., Helminen M., et al. Cranberry juice for the prevention of recurrences of urinary tract infections in children: a randomized placebo-controlled trial Clin Infect Dis 2012; 54(3): 340-6.
  34. Albrecht U., Goos K.H., Schneider B. A randomised, double-blind, placebo-controlled trial of a herbal medicinal product containing Tropaeoli majoris herba (Nasturtium) and Armoraciae rusticanae radix (Horseradish) for the prophylactic treatment of patients with chronically recurrent lower urinary tract infections. Curr Med Res Opin 2007; 23(10): 2415-22.
  35. Williams G., Craig J.C. Prevention of recurrent urinary tract infection in children. Curr Opin Infect Dis 2009; 22(1): 72-6.
  36. Klein T., Abgottspon D., Wittwer M., et al. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J Med Chem 2010; 53(24): 8627-41.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies